Alice S. Mims - Concepedia

Author

Alice S. Mims

The Ohio State University ORCID

Also Known As

A Mims, A. Mims, A.S. Mims, Alice Mims, Alice S Mims, Alice S. Mims, Uma M. Borate

445

Publications

6.6K

Citations

H-Index

Concepts

All Affiliations

The Ohio State University Memorial Sloan Kettering Cancer Center Emory University Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center

About

Alice S. Mims is an author at The Ohio State University specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	24	1.8K
2	Health Sciences	8	8	1.2K
3	Public Health	2	2	111
4	Engineering	1	1	53
5	Social Sciences	1	1	13

Alice S. Mims

Publications

5.8K

Citations

H-Index

Page 1

	Year	Citations
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, New England Journal of Medicine	2018	1.4K
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Journal of the National Comprehensive Cancer Network Hematological MalignancyHealth SciencesMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia	2019	418
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia Gail J. Roboz, Courtney D. DiNardo, Eytan M. Stein, Blood	2019	363
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021 Daniel A. Pollyea, Dale L. Bixby, Alexander E. Perl, Journal of the National Comprehensive Cancer Network Hematological MalignancyTranslational MedicineOncologyMixed-phenotype Acute LeukemiaAcute Myeloid Leukemia	2021	314
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Blood	2020	228
Targeted Delivery of <i>microRNA-29b</i> by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia Xiaomeng Huang, Sebastian Schwind, Bo Yu, Clinical Cancer Research	2013	189
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML Sung Choe, Hongfang Wang, Courtney D. DiNardo, Blood Advances	2020	188
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial Amy Burd, Ross L. Levine, Amy S. Ruppert, Nature Medicine Hematological MalignancyProspective Genomic ProfilingOncologyMedicineAcute Myeloid Leukemia	2020	181
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology Daniel A. Pollyea, Jessica K. Altman, Rita Assi, Journal of the National Comprehensive Cancer Network Hematological MalignancyMedicineAcute Myeloid LeukemiaMixed-phenotype Acute LeukemiaHematology	2023	163
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia Josephine Aimiuwu, Hongyan Wang, Ping Chen, Blood	2012	133

Page 1